Anti-rheumatic treatment and prosthetic joint infection: an observational study in 494 elective hip and knee arthroplasties

Table 4 Periprosthetic joint infection (PJI) and all surgical site infections (SSI) in various subgroups

	Total (n)	PJI (n)	p-value	all SSI (n)	p-value
Female	377	3		14
Male	117	4	0.06^a	5	0.78^b
Procedure
TKA¹	254	7		11
THA²	240	0	0.015^a	8	0.33^b
BMI³, valid no 474
< 30	368	4		12
> 30	106	3	0.19^a	7	0.16 ^b
ASA⁴, valid no 451
< 2	277	3		10
> 3	174	4	0.44^a	8	0.60 ^b
Treatment
Methotrexate	274	4	1.0^a	12	0.49^b
TNF-alpha inhibitor	157	1	0.44^a	5	0.60^b
Prednisolone	214	5	0.25^a	10	0.40^b
Methotrexate and prednisolone	124	2	1.00^a	4	0.79^a
Methotrexate and TNF-inhibitor	90	1	1.00^a	3	1.00^a
Methotrexate, TNF- inhibitor and prednisolone	39	0	1.00^a	0	0.39 ^a
Diagnosis
Rheumatoid arthritis	341	6	0.45^a	16	0.21^a
Psoriatic arthritis	35	1	0.40^a	2	0.64^a
Spondyloarthritis incl. Ankylosing spondylitis	29	0	1.0^a	0	1.0^a
Juvenile idiopathic arthritis	59	0	1.0^a	1	0.76^a
Other diagnosis	30	0	1.0^a	0	1.0^a

¹Total knee-arthroplasty, ²Total hip-arthroplasty, ³Body mass index, ⁴American Society of Anesthesiologists (ASA) Physical Status
^aFisher’s exact test
^bChi-square test

ISSN: 1471-2474